

- **02.16.23 - Bavarian Nordic adding Switzerland plant in \$270m Emergent asset buy ([bioprocessintl](#))**
 - Danish drugmaker Bavarian Nordic has struck a deal to buy numerous vaccine assets from Emergent, including the approved oral vaccines Vivotif and Vaxchora, for typhoid and cholera respectively. Bavarian Nordic will also add late-stage Chikungunya candidate, which could launch in 2025. The 16,000 m² plant has capabilities for mammalian, microbial, viral drug substance, and drug product production, and includes a bacterial fermenter to a 4,000 L scale, 200 L cell culture equipment, a large-scale bulk lyophilizer, and production lines that include harvest capabilities by flow-through centrifuge or tangential flow filtration (TFF) system. The firm also said the plant would expand its European GMP manufacturing footprint, allow the introduction of new technologies, and complement its current capabilities in Kvistgaard, Denmark. The Danish site has recently undergone a \$75 million expansion to add a fill/finish facility.
- **02.14.23 - A biomanufacturing site is coming to Canada's Prince Edward Island ([endpts](#))**
 - The governments of Canada and Prince Edward Island are placing a CAN 50 million (\$37.4 million) investment into what is being dubbed the BioAccelerator, with the project being spearheaded by Prince Edward Island BioAlliance, a local business organization. According to an email from a PEI BioAlliance spokesperson, both the Canadian government and the local government contributed CAN 25 million (\$18.7 million) to the project. This will be a new 75,000-square-foot biomanufacturing facility, allowing Canadian biotechs to carry out R&D operations as well as build out any manufacturing operations. The site will also provide access to manufacturing training. According to the email from PEI BioAlliance, the site will have expertise from the National Research Council and the Canadian Alliance for Skills and Training in Life Sciences.
- **02.14.23 - Lonza opens US lab as part of early development services expansion ([fiercepharma](#))**
 - Lonza is opening a new laboratory in Cambridge, Massachusetts, as part of the Swiss CDMO's plan to expand its early development services (EDS) division in North America. The 17,000-square-foot facility is expected to begin operating in May and complements the company's existing EDS facility located in Cambridge, U.K
- **02.10.23 - Evotec receives € 150 m loan from European Investment Bank ([PR](#))**
 - Through this new financing of € 150 m, the EIB reiterates its supports to Evotec, a company that it already supported in 2017 with a financing of € 75 m. This new agreement is to be signed in Toulouse during a visit of the site on which the new biologics manufacturing facility will be built. The EIB funding specifically supports Evotec's business strategy through a unique, innovative and flexible financing structure including a low fixed interest rate plus a reward-sharing component for the EIB. The loan with a total volume of up to € 150 m will be invested over a period of three years and each tranche will mature seven years after draw down. Evotec will use the financing to fund its internal R&D activities, equity investments, as well as the new biologics manufacturing facility, J.POD® Toulouse, France (EU).
- **02.07.23 - Thermo Fisher Scientific launches Cell Therapy Collaboration Center Program in Singapore to accelerate therapy development across Asia Pacific ([PR](#))**
 - Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of its new Cell Therapy Collaboration Center Program in Singapore to accelerate cell therapy development across the Asia Pacific region. The center, based in Singapore, will serve as the Asia Pacific hub to provide cell and gene therapy (CGT) developers with tailored support on their path to clinical manufacturing and commercial success.
- **02.10.23 - Genentech to start construction on a new manufacturing facility in CA ([Endpts](#))**
 - Roche's Genentech has broken ground on a new manufacturing site in Southern California. The pharma said on Friday that it is starting construction on a new facility to manufacture biologics at its campus in Oceanside, CA, north of San Diego. Genentech is investing hundreds of millions into manufacturing at the Oceanside facility and plans to add 150 jobs, the company said in a release. The campus sits on 60 acres and has around 575,000 square feet slated for manufacturing. Dertsakian said that by the time it's completed, Genentech will have invested over \$280 million in the new facility, which is part of a larger investment of an estimated \$450 million in Oceanside. Genentech is investing another estimated \$250 million in its facility in South San Francisco, CA. Nazeli Dertsakian, VP and general manager of the Oceanside Biologics operations, said in an email to Endpoints News that currently the site manufactures Xolair for asthma, but it is licensed to manufacture some oncology medicines as well. The new facility will make antibodies and protein-based medicines for commercial use, although the exact products have not been determined yet. The site will cover around 84,000 square feet, and construction is expected to finish in late 2024 with an opening date in early 2025.
- **02.10.23 - Japan cancels 140M dose order for Novavax Covid vaccine amid 'lower than expected' demand ([endpts](#))**
 - The country initially agreed in 2021 to purchase 150 million doses of the vaccine from Takeda, which has been producing Novavax's vaccine at its Hikari-based facility. But after only purchasing 8.24 million doses, the Ministry of Health, Labour and Welfare has canceled the remaining 141.76 million doses. Because the doses were being manufactured as orders from the government came in, there will be no "disposal" of doses as a result of the cancelation, Takeda said in the filing on Friday.

- 02.02.23 - BioNTech Strengthens Manufacturing Capabilities with First In-House Plasmid DNA Manufacturing Facility in Germany ([PR](#))
 - Plasmids are an important starting material for the manufacturing of mRNA- and cell-based drugs. The new plasmid manufacturing facility aims to increase BioNTech's autonomy and flexibility in manufacturing an important starting material for its oncology and COVID-19 vaccine pipeline. The investment of approximately €40 million is part of a long-term development plan for BioNTech's manufacturing site in Marburg, Germany.
- 02.01.23 - Seqens Group Opens Flagship Pharmaceutical R&D Center in Greater Boston ([PR](#))
 - Seqens Group, an integrated leader in the development and manufacture of active pharmaceutical ingredients (APIs) and intermediates, today announced that it has opened Seqens Boston R&D Center, a state-of-the-art, 15,000 square-foot R&D center in Devens, Mass. Serving as one of the company's global centers of excellence, the new facility will bring customers advanced capabilities for the discovery and development of new drugs and therapeutics. The \$5 million investment ensures that the new facility will leverage the most advanced technologies, equipment and design, while adhering to the highest levels of quality, sustainability and safety. The new lab replaces an older, smaller R&D facility in Devens, and all current employees have moved to the new lab. Seqens plans to double the number of scientists there by 2026.

About Berke Search

The Berke Executive Search team is comprised of seasoned and engaged partners who lead our highly specialized firm with an unwavering commitment to excellence and integrity. With over two decades of experience conducting searches for C-Suite, Senior Commercial, Scientific Leadership, and specialized functional leadership disciplines, we have developed deep relationships and a large network of top talent. Our deep experience and expertise benefits clients by shrinking timelines and lowering talent acquisition costs. In addition, our nimble size (boutique) and highly selective client base virtually eliminate conflict of interest and off-limit issues; we execute only a select number of search pools to ensure our resources are maximized and enable superior success rates.

Visit us at Berkesearch.com